BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35088997)

  • 41. [Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer: a technique to reduce morbidity].
    Aufderklamm S; Todenhöfer T; Hennenlotter J; Gakis G; Mischinger J; Mundhenk J; Germann M; Stenzl A; Schwentner C
    Urologe A; 2013 Aug; 52(8):1097-103. PubMed ID: 23416965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy.
    Konneh B; Leonard AJ; Lafin JT; Jia L; Bagrodia A
    Oncology (Williston Park); 2022 Jun; 36(6):375-377. PubMed ID: 35723941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.
    Chanal E; Bouleftour W; Guillot A; Rowinski E; Bernichon E; Tremeau L; Lardon R; Lacroix B; Lorin S; Delorme G; Perraud Y; Armand C; Levigne F; Vallard A; Langrand-Escure J; Fournel P; Benoite M; Vassal C
    Bull Cancer; 2019 Dec; 106(12):1086-1093. PubMed ID: 31582176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D; Ondrusova M; Hornak M; Matoska J
    Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
    Ondrus D; Hornák M; Breza J; Mat'oska J; Schnorrer M; Belan V; Kausitz J
    Int Urol Nephrol; 2001; 32(4):665-7. PubMed ID: 11989561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
    Fosså SD; Qvist H; Stenwig AE; Lien HH; Ous S; Giercksky KE
    J Clin Oncol; 1992 Apr; 10(4):569-73. PubMed ID: 1312586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
    Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
    J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
    Yoon GH; Stein JP; Skinner DG
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
    Pizzocaro G; Zanoni F; Salvioni R; Milani A; Piva L; Pilotti S
    J Urol; 1987 Dec; 138(6):1393-6. PubMed ID: 2824862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Two cases of giant testicular tumor with widespread extension to the spermatic cord: usefulness of upfront chemotherapy].
    Kin T; Kitsukawa S; Shishido T; Maeda Y; Izutani T; Yonese J; Fukui I
    Hinyokika Kiyo; 1999 Mar; 45(3):191-4. PubMed ID: 10331173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
    Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
    J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preservation of retroperitoneal lymph nodes in patients with locoregional nonseminomatous germ cell tumors: surveillance and primary chemotherapy.
    von Eschenbach AC; Swanson DA; Johnson DE; Wishnow KI; Stephenson RA; Babaian RJ
    Prog Clin Biol Res; 1991; 370():385-92. PubMed ID: 1718009
    [No Abstract]   [Full Text] [Related]  

  • 57. [Initial chemotherapy followed by orchiectomy and retroperitoneal lymphadenectomy--a case of seminoma with a testicular tumor and enlarged regional lymph nodes].
    Onishi T; Nakano S; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1994 Feb; 40(2):151-4. PubMed ID: 7510450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Aortic replacement during post chemotherapy retroperitoneal residual tumor resection for nonseminomatous germ cell tumor: a case report].
    Matsuzaki M; Nakano M; Komatsu H; Ohashi K
    Hinyokika Kiyo; 2005 Dec; 51(12):831-4. PubMed ID: 16440734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
    Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
    Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.